

S 164

Advancing Education on Biosimilars Act of 2021

Congress: 117 (2021–2023, Ended)

Chamber: Senate

Policy Area: Health

Introduced: Feb 2, 2021

Current Status: Became Public Law No: 117-8.

Latest Action: Became Public Law No: 117-8. (Apr 23, 2021)

Law: 117-8 (Enacted Apr 23, 2021)

Official Text: <https://www.congress.gov/bill/117th-congress/senate-bill/164>

Sponsor

Name: Sen. Hassan, Margaret Wood [D-NH]

Party: Democratic • **State:** NH • **Chamber:** Senate

Cosponsors (1 total)

Cosponsor	Party / State	Role	Date Joined
Sen. Cassidy, Bill [R-LA]	R - LA		Feb 2, 2021

Committee Activity

Committee	Chamber	Activity	Date
Health, Education, Labor, and Pensions Committee	Senate	Discharged From	Mar 3, 2021

Subjects & Policy Tags

Policy Area:

Health

Related Bills

Bill	Relationship	Last Action
117 HR 19	Related bill	Oct 19, 2021: Referred to the Subcommittee on Antitrust, Commercial, and Administrative Law.
117 HR 1873	Identical bill	Mar 16, 2021: Referred to the Subcommittee on Health.

Advancing Education on Biosimilars Act of 2021

This bill requires the Food and Drug Administration (FDA) to advance education and awareness among health care providers about biological products as appropriate, including by developing or improving continuing education programs that address the prescribing of biological products and biosimilars. (A biosimilar is a biological product that is highly similar to an FDA-approved reference biological product and has no clinically meaningful differences from that reference product.)

The FDA may also maintain and operate a website to provide educational materials about biological products.

Actions Timeline

- **Apr 23, 2021:** Signed by President.
- **Apr 23, 2021:** Became Public Law No: 117-8.
- **Apr 20, 2021:** Presented to President.
- **Apr 14, 2021:** Mr. Pallone moved to suspend the rules and pass the bill.
- **Apr 14, 2021:** Considered under suspension of the rules. (consideration: CR H1754-1755)
- **Apr 14, 2021:** DEBATE - The House proceeded with forty minutes of debate on S. 164.
- **Apr 14, 2021:** At the conclusion of debate, the Yeas and Nays were demanded and ordered. Pursuant to the provisions of clause 8, rule XX, the Chair announced that further proceedings on the motion would be postponed.
- **Apr 14, 2021:** Considered as unfinished business. (consideration: CR H1783-1784)
- **Apr 14, 2021:** Passed/agreed to in House: On motion to suspend the rules and pass the bill Agreed to by the Yeas and Nays: (2/3 required): 412 - 8 (Roll no. 101).(text: CR H1754)
- **Apr 14, 2021:** On motion to suspend the rules and pass the bill Agreed to by the Yeas and Nays: (2/3 required): 412 - 8 (Roll no. 101). (text: CR H1754)
- **Apr 14, 2021:** Motion to reconsider laid on the table Agreed to without objection.
- **Mar 8, 2021:** Message on Senate action sent to the House.
- **Mar 8, 2021:** Received in the House.
- **Mar 8, 2021:** Held at the desk.
- **Mar 3, 2021:** Senate Committee on Health, Education, Labor, and Pensions discharged by Unanimous Consent.(consideration: CR S1021)
- **Mar 3, 2021:** Senate Committee on Health, Education, Labor, and Pensions discharged by Unanimous Consent. (consideration: CR S1021)
- **Mar 3, 2021:** Passed/agreed to in Senate: Passed Senate without amendment by Unanimous Consent.(text: CR S1021)
- **Mar 3, 2021:** Passed Senate without amendment by Unanimous Consent. (text: CR S1021)
- **Feb 2, 2021:** Introduced in Senate
- **Feb 2, 2021:** Read twice and referred to the Committee on Health, Education, Labor, and Pensions.